Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression
Yanxiao Sun, Longtao Zhang, Dong Guo · 2026
Read Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression by Yanxiao Sun, Longtao Zhang, Dong Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13278892.txt.
Description
Yanxiao Sun, Longtao Zhang, and Dong Guo compare first-line immunotherapy combinations for metastatic triple-negative breast cancer, in a 2026 network meta-analysis. Eight randomised trials with 3,789 patients and six regimens were pooled. PD-L1, a marker on tumour cells, may decide who gains most.
Adding checkpoint inhibitors to chemotherapy improved survival and delayed progression across the whole group. Serious side effects rose slightly without reaching statistical significance. Benefits grew stronger as PD-L1 levels rose, with the highest group gaining most. One regimen, toripalimab with chemotherapy, showed the largest survival gain in the overall population. The authors rank options while noting that several estimates carry wide uncertainty.
Catalog record
| CREATOR | Yanxiao Sun, Longtao Zhang, Dong Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |